Vera Therapeutics, Inc.
NASDAQ:VERABiotechnology
+$0.09 today
- Market cap
- $1.85B
- Beta
- 0.95
- P/E (TTM)
- -6.8
- EPS (TTM)
- -$5.16
Volume 0.95M
Average 1.18M
VERA Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Vera Therapeutics, Inc.NASDAQ: VERA
Operating Expenses · Q2 FY2026 · quarter ended Jun 2026
Operating expenses grows, but more slowly than its trailing trend
Q2 FY2026 operating expenses of $112.49M rose 40.4% year over year, behind the +76.1% change in trailing-twelve-month operating expenses. Sequentially, it fell 10.1% from the prior quarter. Over 3 fiscal years it compounded at +50.9% a year.
Context
- Operating expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +40.4% toward the trailing-twelve-month pace of +76.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 315.47M USD
- Year-over-year change
- +88.7%
- 4-year CAGR
- +74.0%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 315.47M | +88.7% |
| FY2024 | 2024-12-31 | 167.17M | +63.9% |
| FY2023 | 2023-12-31 | 102.01M | +11.2% |
| FY2022 | 2022-12-31 | 91.75M | +166.7% |
| FY2021 | 2021-12-31 | 34.4M | — |
Operating Expenses vs competitors
How VERA compares with its peers on the latest reported figures
- VERA's LTM Jun 2026 operating expenses of $415.76M is the 3rd highest of the 10 companies compared; the peer median is $265.04M.
- Its year-over-year change of +76.1% is the 2nd highest of 10, against a peer median of +21.2%.
- Over three fiscal years its annual growth of +50.9% compares with a peer median of +55.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $565.38M | -29.4% | +9.3% | — | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $465.53M | +1.6% | +58.0% | 6292.6% |
| LTM Jun 2026 | $415.76M | +76.1% | +50.9% | — | |
| LTM Jun 2026 | $388.63M | +21.2% | +4.9% | 83.8% | |
| LTM Mar 2026 | $299.02M | +4.7% | +22.2% | 81.0% | |
| LTM Mar 2026 | $265.04M | +55.2% | +55.0% | — | |
| LTM Mar 2026 | $229.74M | +420.0% | +71.3% | 98.9% | |
| LTM Jun 2026 | $219.67M | +63.0% | +70.8% | 11537.4% | |
| LTM Mar 2026 | $162.92M | +24.9% | +67.1% | — | |
| LTM Mar 2026 | $86.87M | -40.0% | -8.6% | 1038.2% | |
| Peer median (excluding VERA) | $265.04M | +21.2% | +55.0% | 568.6% | |
Competitors are the stored peer set for VERA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | (846K) | 0 | 0 | 0 |
| Gross Profit | 0 | 846K | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 22.48M | 69.84M | 78.23M | 126.17M | 215.26M |
| Selling, General & Admin | 11.92M | 21.91M | 23.79M | 41M | 100.22M |
| Operating Expenses | 34.4M | 91.75M | 102.01M | 167.17M | 315.47M |
| Depreciation & Amortization | 176K | (846K) | 21K | 105K | 468K |
| EBITDA | (32.41M) | (88.91M) | (92.18M) | (144.42M) | (291.62M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (34.4M) | (90.9M) | (102.01M) | (167.17M) | (315.47M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 15K | 1.75M | 7.98M | 20.71M | 24.48M |
| Interest Expense | 20K | 992K | 3.79M | 7.63M | 7.53M |
| Other Income / Expenses | 1.79M | 1.85M | 6.02M | 15.02M | 15.86M |
| Income Before Tax | (32.61M) | (89.06M) | (95.99M) | (152.15M) | (299.61M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 1K | 1K | 1K | 1K | 1K |
| Net Income | (32.61M) | (89.06M) | (95.99M) | (152.15M) | (299.62M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.43) | (3.35) | (2.25) | (2.75) | (4.66) |
| EPS (Diluted) | (2.43) | (3.35) | (2.25) | (2.75) | (4.66) |
| Weighted Avg Shares | 13.44M | 26.57M | 42.71M | 55.33M | 64.23M |
| Weighted Avg Shares (Diluted) | 13.44M | 26.57M | 42.71M | 55.33M | 64.23M |
Vera Therapeutics, Inc.
NASDAQ:VERA
Intrinsic Alpha fair value
Locked
Current Price
$25.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.